BLUE BELL, Pa., Nov. 7, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended September 30, 2012.
Total revenue was $855,000 and $3.0 million for the three and nine months ended September 30, 2012, compared to $2.6 million and $8.2 million for the same periods in 2011.
Total operating expenses were $7.1 million and $20.3 million for the three and nine months ended September 30, 2012, compared to $9.0 million and $24.0 million for the same periods in 2011.
The net loss attributable to common stockholders for the three and nine months ended September 30, 2012, was $6.6 million, or $0.05 per share, and $19.0 million, or $0.14 per share, compared to a net loss of $4.5 million, or $0.04 per share, and $9.8 million, or $0.08 per share, for the three and nine months ended September 30, 2011.
The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $453,000 and $2.2 million for the three and nine months ended September 30, 2012, versus $1.9 million and $6.4 million for the same periods in 2011. This NIAID contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.
Research and development expenses for the three and nine months ended September 30, 2012, were $5.0 million and $13.5 million for the three and nine months ended September 30, 2012, compared to $7.0 million and $15.9 million for the same periods in 2011. General and administrative expenses for the three and nine months ended September 30, 2012, were $2.7 million and $7.9 million versus $2.3 million and $8.7 million for the same periods in 2011.
Net Loss Attributable to Common Stockholders
The $2.1 million and $9.2 million increase in net loss for the three and nine months ended September 30, 2012, respectively, compared with the same periods in 2011, resulted primarily from a significant (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price, and a decrease in grant revenue.
As of September 30, 2012, cash and cash equivalents plus short-term investments in certificates of deposit, mutual funds, and municipal bonds were $15.2 million compared with $30.3 million as of December 31, 2011.
Based on management's projections and analysis, the Company believes that current cash and cash equivalents plus short-term investments are sufficient to meet its planned working capital requirements into the third quarter of 2013.
During the third quarter, the Company sold 2,086,986 shares of common stock under its ATM common stock sales agreement for net proceeds of $1.2 million.
Inovio's balance sheet and statement of operations are provided below. Form 10-Q providing the complete 2012 third quarter financial report can be found at: http://ir.inovio.com/secfilings.
Inovio's mission is to revolutionize vaccines by achieving two critical capabilities: enabling vaccines to provide not only preventive but treatment capabilities; and enabling universal protection against multiple known and unknown strains rather than just a single known virus strain in order to provide better protection against mutating virus strains. During the third quarter, Inovio reported important scientific and clinical breakthroughs on both fronts.
With respect to the treatment potential of its novel synthetic vaccines, Inovio reported that its SynCon® vaccine against cervical dysplasias and cancers (VGX-3100) achieved an industry first when T-cell immune responses induced by this vaccine, which have been previously reported as being best-in-class, were also shown to generate a strong killing effect against cells targeted by this vaccine. Enrollment is ongoing in Inovio's phase II clinical study of VGX-3100 for cervical dysplasia. Data is expected in late 2013.
Two Inovio collaborators, the University of Southampton and ChronTech Pharma AB, are expected to report interim data from their phase II studies of DNA vaccines for leukemia and hepatitis C virus, respectively, before the end of 2012. Both of these vaccines are also designed to generate T-cell responses to provide therapeutic benefits.
With respect to the universal prevention capability of its vaccine platform, Inovio reported that its H1N1 influenza vaccine "construct" generated protective immune responses in humans against the nine key H1N1 flu strains of the past 100 years, including the 1918 pandemic flu strain. None of these viruses were matched to the vaccine. These results added to the Q2 reported results in which Inovio's H5N1 (avian) influenza vaccine construct generated significant immune responses against six different unmatched strains of H5N1 in a human clinical trial. Together these results also represent an industry first and a major stride toward universal vaccines for influenza as well as other rapidly changing viruses such as HIV. Inovio expects to report additional data from the H1N1 study in 1Q 2013.
Inovio also treated the first patients in its third influenza clinical trial, this one evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon® universal influenza vaccine. The 65+ age group represents about 90% of annual influenza deaths in the US. Interim data from this study is expected in the first half of 2013.
Corporate & Business Development
Inovio continues to advance discussions with large pharmaceutical companies with the goal of securing strategic partnerships to advance the development of SynCon® vaccines.
Inovio's VGX Animal Health subsidiary reported advancements for its growth hormone releasing hormone (GHRH) treatment focused on enhancing the health and food production efficiency of farm animals. The Company was granted marketing approval in New Zealand for its high-dose plasmid therapy that increases live births in pigs. This therapy was previously approved in Australia. The Company also reported that its new low-dose version of this therapy, LifeTide® SW 1.0, resulted in more live pigs per litter and higher birth and weaning weights.
Inovio Pharmaceuticals was also named Best Mid-Stage Product Development Company by the Philadelphia Business Journal.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.